Welcome to our dedicated page for Leap Therapeutic news (Ticker: LPTX), a resource for investors and traders seeking the latest updates and insights on Leap Therapeutic stock.
Leap Therapeutics, Inc. (Nasdaq: LPTX) is a clinical-stage biopharmaceutical company advancing targeted therapies for challenging cancers. This page provides investors and researchers with direct access to official announcements and verified updates about the company’s oncology programs.
Key resources include: Clinical trial progress for lead candidate DKN-01 (targeting DKK1), developments in FL-301 (Claudin18.2 program), partnership announcements, and financial disclosures. All content is sourced from authorized releases to ensure reliability.
Users benefit from: Timely updates on regulatory milestones, research collaborations, and pipeline advancements in gastrointestinal/gastroesophageal cancers. Content is organized chronologically for efficient tracking of material events.
Bookmark this page to monitor Leap Therapeutics’ progress in developing precision antibody therapies, with new updates added as official announcements become available.
Leap Therapeutics, Inc. (LPTX) reported a net loss of $15.1 million for Q3 2022, up from $11.1 million in Q3 2021. Research and development expenses increased to $12.1 million, primarily due to higher clinical trial costs and increased headcount. General and administrative expenses rose to $3.2 million, attributed to increased professional fees and payroll expenses. On a positive note, Leap presented promising clinical data for DKN-01 in combination therapies for gastroesophageal adenocarcinoma, with compelling overall response rates and median progression-free survival exceeding benchmarks.
Leap Therapeutics (LPTX) announced promising results from the DisTinGuish study, showing a 55% overall response rate (ORR) and a 73% disease control rate (DCR) in DKK1-high gastroesophageal adenocarcinoma patients treated with DKN-01 and tislelizumab. The combination therapy demonstrated a median progression-free survival of 7.7 months. Additionally, the company presented preclinical data indicating DKN-01's efficacy in colorectal cancer models, with expectations of initial results from the DeFianCe study in mid-2023.
Leap Therapeutics (NASDAQ: LPTX) has enrolled its first patient in the Phase 2 DeFianCe study of DKN-01, an anti-DKK1 antibody, for treating advanced colorectal cancer (CRC). This study combines DKN-01 with bevacizumab and chemotherapy, targeting patients with prior systemic therapy. The trial seeks to assess progression-free survival among other objectives, with initial data expected by mid-2023. DKN-01 aims to combat resistance to chemotherapy in CRC. Colorectal cancer remains a leading global health challenge, highlighting the urgency of new treatment options.
Leap Therapeutics (Nasdaq:LPTX) has announced the enrollment of the first patient in Part C of the Phase 2 DisTinGuish study, which evaluates DKN-01, an anti-DKK1 antibody, combined with BeiGene's tislelizumab and chemotherapy in patients with gastric or gastroesophageal junction cancer. The study aims to enroll 160 patients and assess progression-free survival, particularly in patients with high DKK1 expression. Positive preliminary data indicate promising response rates and survival outcomes surpassing benchmarks, marking a significant step in DKN-01's clinical development.
Leap Therapeutics, Inc. (Nasdaq: LPTX) will present updated data from Part B of the DisTinGuish Study evaluating DKN-01 combined with tislelizumab for DKK1-high GEJ/G cancer patients at the SITC 37th Annual Meeting in Boston from November 8-12, 2022. Additionally, preclinical data supporting the DeFianCe Study of DKN-01 in advanced colorectal cancer will also be shared. DKN-01, a humanized monoclonal antibody targeting DKK1, is being developed for multiple cancer types, with a strategic collaboration with BeiGene for development rights in Asia, excluding Japan.
Leap Therapeutics, Inc. (Nasdaq: LPTX) announced that CEO Douglas E. Onsi will participate in a fireside chat at the Baird 2022 Global Healthcare Conference in New York on September 13-14, 2022. The chat is scheduled for September 13 at 3:10 p.m. Eastern Time and will be webcast live, with a replay available on the company’s website. Leap specializes in developing targeted and immuno-oncology therapeutics, notably its candidate DKN-01, which targets the DKK1 protein and is currently in clinical trials for various cancers.
Leap Therapeutics (NASDAQ: LPTX) announced the appointment of Richard L. Schilsky, MD, to its Board of Directors, effective September 1, 2022. Dr. Schilsky has over 40 years of experience in cancer research and drug development, previously serving as Chief Medical Officer of ASCO. His expertise is expected to enhance Leap's drug development strategy, particularly for DKN-01, a monoclonal antibody aimed at treating solid tumors. The company continues to advance its pipeline and aims to deliver impactful therapies.
Leap Therapeutics, Inc. (NASDAQ: LPTX) announced promising results from its DisTinGuish study for DKN-01 combined with tislelizumab and CAPOX in first-line gastric cancer, showing a median progression-free survival of 11.3 months. The study demonstrated favorable outcomes for DKK1-high and PD-L1-low subgroups. Additionally, the WAKING study, evaluating DKN-01 with Tecentriq, is ongoing. Safety profiles were consistent, with high overall response rates, particularly in DKK1-high patients. Leap aims to advance DKN-01's clinical development, enhancing treatment standards for advanced gastroesophageal cancers.
Leap Therapeutics, Inc. (NASDAQ: LPTX) reported its Q2 2022 financial results, highlighting significant advancements in clinical trials for its lead product DKN-01. The company initiated Part C of the DisTinGuish study, evaluating DKN-01 alongside BeiGene's tislelizumab in G/GEJ cancer patients. Additionally, a new study in second-line colorectal cancer and an investigator-initiated trial with pembrolizumab were announced. Leap ended Q2 with $90.9 million in cash, providing a financial runway into mid-2024. Net loss for the quarter was $17.0 million, up from $9.5 million a year earlier, primarily due to rising clinical trial costs.
Leap Therapeutics, Inc. (Nasdaq:LPTX) announces the transition of Board member Dr. Monica Bertagnolli, recently appointed as the 16th Director of the National Cancer Institute (NCI), marking the first woman to hold this position since 1937. Effective immediately, Dr. Bertagnolli steps down from Leap's Board, following a commendable tenure. The company expresses pride in her achievement, recognizing her significant contributions to cancer research and leadership. Leap Therapeutics focuses on immuno-oncology therapeutics, notably developing DKN-01 for various cancers in partnership with BeiGene, Ltd.
FAQ
What is the current stock price of Leap Therapeutic (LPTX)?
What is the market cap of Leap Therapeutic (LPTX)?
